{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:39:19Z","timestamp":1765805959696},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Zollinger-Ellison syndrome (ZES) is a rare condition characterized by hypersecretion of gastrin by gastrinoma tumors leading to severe peptic ulcer disease with potential development of gastric carcinoid tumors. Herein, we report the clinical course of a 68-year-old patient with multiple endocrine neoplasia type 1 (MEN-1) who underwent several surgeries to ultimately undergo optimal tumor cytoreduction of locally advanced gastrinomas and symptomatic gastric carcinoids. The patient was subsequently maintained on octreotide long-acting release (LAR). This case report supports consideration for aggressive tumor cytoreduction and octreotide in similar patients with MEN-1-associated ZES for durable disease control and symptom management.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>The patient is a 68-year-old male with multiple endocrine neoplasia type 1 (MEN-1), diagnosed in 1993 after presenting with recurrent renal calculi and hypercalcemia. Soon thereafter, he presented with symptoms and elevated gastrin levels suggestive of ZES prompting abdominal exploration with partial resection of the duodenum to remove gastrinoma tumor nodules. Within 4\u2009years of the operation, he represented with intractable hypergastrinemia despite optimal medical management with peak gastrin levels exceeding 29,000\u2009pg\/mL, in 2006. In January 2007, the patient returned to the operating room for resection of regional peripancreatic and perigastric lymph nodes and enucleation of pancreatic body and tail gastrinoma tumors. Although his gastrin level decreased to 5000\u2009pg\/mL with resultant improvement of symptoms, in less than 2\u2009years, he developed disease progression with obstructive symptomatology from enlarging gastric carcinoids and rising gastrin levels. In May of 2008, he underwent pancreaticoduodenectomy and near-total gastrectomy. Since June of 2008, the patient shows no demonstrable progression of disease and remains asymptomatic on LAR octreotide (30\u00a0mgs). Gastrin levels have been well controlled (range, 100\u2013624\u2009pg\/mL; current 114\u2009pg\/mL).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Success of this procedure in our case report highlights the potential role for optimal tumor cytoreduction and LAR octreotide to control disease progression in a patient with MEN-I and Zollinger-Ellison syndrome with locally advanced gastrinoma and secondary large gastric carcinoids.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12957-019-1758-6","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T19:04:13Z","timestamp":1575918253000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: optimal tumor cytoreduction and octreotide with durable disease control in a patient with MEN-1 and Zollinger-Ellison syndrome\u2014over a decade of follow-up"],"prefix":"10.1186","volume":"17","author":[{"given":"Lynsey M.","family":"Daniels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William F.","family":"Morano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Simoncini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth C.","family":"Mapow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Leaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbur B.","family":"Bowne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"issue":"19-20","key":"1758_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00508-007-0881-5","volume":"119","author":"M Behe","year":"2007","unstructured":"Behe M, Gotthardt M, Behr TM. Imaging of gastrinomas by nuclear medicine methods. Wiener klinische Wochenschrift. 2007;119(19-20):593\u20136.","journal-title":"Wiener klinische Wochenschrift."},{"issue":"1","key":"1758_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12020-017-1420-4","volume":"60","author":"V Guarnotta","year":"2018","unstructured":"Guarnotta V, Martini C, Davi MV, Pizza G, Colao A, Faggiano A. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? Endocrine. 2018;60(1):15\u201327.","journal-title":"Endocrine"},{"key":"1758_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yasu.2013.02.004","volume":"47","author":"GW Krampitz","year":"2013","unstructured":"Krampitz GW, Norton JA. Current management of the Zollinger-Ellison syndrome. Advances in surgery. 2013;47:59\u201379.","journal-title":"Advances in surgery."},{"issue":"5","key":"1758_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1097\/01.sla.0000143252.02142.3e","volume":"240","author":"JA Norton","year":"2004","unstructured":"Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240(5):757\u201373.","journal-title":"Ann Surg"},{"issue":"6","key":"1758_CR5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.surg.2004.06.057","volume":"136","author":"JA Norton","year":"2004","unstructured":"Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2004;136(6):1267\u201374.","journal-title":"Surgery"},{"issue":"1","key":"1758_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00268-005-0341-1","volume":"30","author":"M Imamura","year":"2006","unstructured":"Imamura M, Komoto I, Ota S. Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome. World J Surg. 2006;30(1):1\u201311.","journal-title":"World J Surg"},{"issue":"1","key":"1758_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1053\/gast.2002.34231","volume":"123","author":"PL Peghini","year":"2002","unstructured":"Peghini PL, Annibale B, Azzoni C, Milione M, Corleto VD, Gibril F, et al. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology. 2002;123(1):68\u201385.","journal-title":"Gastroenterology"},{"issue":"7","key":"1758_CR8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s00268-004-7345-0","volume":"28","author":"ML Richards","year":"2004","unstructured":"Richards ML, Gauger P, Thompson NW, Giordano TJ. Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas. World J Surg. 2004;28(7):652\u20138.","journal-title":"World J Surg"},{"issue":"3","key":"1758_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1530\/ERC-15-0490","volume":"23","author":"ME Caplin","year":"2016","unstructured":"Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016;23(3):191\u20139.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"1758_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000443612","volume":"104","author":"A Rinke","year":"2017","unstructured":"Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results of Long-Term Survival. Neuroendocrinol. 2017;104(1):26\u201332.","journal-title":"Neuroendocrinol"},{"issue":"6","key":"1758_CR11","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/gut.29.6.838","volume":"29","author":"P Ruszniewski","year":"1988","unstructured":"Ruszniewski P, Girard F, Benamouzig R, Mignon M, Bonfils S. Long acting somatostatin treatment of paraneoplastic Cushing's syndrome in a case of Zollinger-Ellison syndrome. Gut. 1988;29(6):838\u201342.","journal-title":"Gut"},{"issue":"2","key":"1758_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/cncr.10195","volume":"94","author":"H Shojamanesh","year":"2002","unstructured":"Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer. 2002;94(2):331\u201343.","journal-title":"Cancer"},{"issue":"8","key":"1758_CR13","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1056\/NEJM200008243430805","volume":"343","author":"P Tomassetti","year":"2000","unstructured":"Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med. 2000;343(8):551\u20134.","journal-title":"N Engl J Med"},{"issue":"3","key":"1758_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s005350050267","volume":"34","author":"S Kamoshida","year":"1999","unstructured":"Kamoshida S, Saito E, Fukuda S, Kato K, Iwasaki A, Arakawa Y. Anatomical location of enterochromaffin-like (ECL) cells, parietal cells, and chief cells in the stomach demonstrated by immunocytochemistry and electron microscopy. J Gastroenterol. 1999;34(3):315\u201320.","journal-title":"J Gastroenterol"},{"issue":"3","key":"1758_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ecl.2018.04.013","volume":"47","author":"S Grozinsky-Glasberg","year":"2018","unstructured":"Grozinsky-Glasberg S, Alexandraki KI, Angelousi A, Chatzellis E, Sougioultzis S, Kaltsas G. Gastric Carcinoids. Endocrinol Metab Clin North Am. 2018;47(3):645\u201360.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"1758_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11894-017-0572-y","volume":"19","author":"S Sundaresan","year":"2017","unstructured":"Sundaresan S, Kang AJ, Merchant JL. Pathophysiology of Gastric NETs: role of gastrin and menin. Current gastroenterology reports. 2017;19(7):32.","journal-title":"Current gastroenterology reports."},{"issue":"6","key":"1758_CR17","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.1997.15.6.2420","volume":"15","author":"VE Sutliff","year":"1997","unstructured":"Sutliff VE, Doppman JL, Gibril F, Venzon DJ, Yu F, Serrano J, et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol. 1997;15(6):2420\u201331.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1758_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/01.sla.0000164073.08093.5d","volume":"241","author":"JP Boudreaux","year":"2005","unstructured":"Boudreaux JP, Putty B, Frey DJ, Woltering E, Anthony L, Daly I, et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg. 2005;241(6):839\u201345 discussion 45-6.","journal-title":"Ann Surg"},{"issue":"8","key":"1758_CR19","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00423-011-0828-1","volume":"396","author":"CL Lopez","year":"2011","unstructured":"Lopez CL, Waldmann J, Fendrich V, Langer P, Kann PH, Bartsch DK. Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1. Langenbecks Arch Surg. 2011;396(8):1187\u201396.","journal-title":"Langenbecks Arch Surg"},{"issue":"11","key":"1758_CR20","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.1210\/jcem.86.11.8011","volume":"86","author":"F Gibril","year":"2001","unstructured":"Gibril F, Venzon DJ, Ojeaburu JV, Bashir S, Jensen RT. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab. 2001;86(11):5282\u201393.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1758_CR21","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0039-6060(96)80055-9","volume":"120","author":"Nora T. Jaskowiak","year":"1996","unstructured":"Jaskowiak NT, Fraker DL, Alexander HR, Norton JA, Doppman JL, Jensen RT. Is reoperation for gastrinoma excision indicated in Zollinger-Ellison syndrome? Surgery 1996;120(6):1055-1062; discussion 62-3.","journal-title":"Surgery"},{"issue":"2","key":"1758_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.6004\/jnccn.2006.0015","volume":"4","author":"JA Norton","year":"2006","unstructured":"Norton JA, Fang TD, Jensen RT. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Canc Netw. 2006;4(2):148\u201353.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1758_CR23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1634\/theoncologist.2013-0369","volume":"19","author":"I Epelboym","year":"2014","unstructured":"Epelboym I, Mazeh H. Zollinger-Ellison syndrome: classical considerations and current controversies. Oncol. 2014;19(1):44\u201350.","journal-title":"Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-019-1758-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12957-019-1758-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-019-1758-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:40:35Z","timestamp":1607388035000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-019-1758-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1758"],"URL":"https:\/\/doi.org\/10.1186\/s12957-019-1758-6","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"15 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from the patient and all co-authors. Written informed consent obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}